Lv0
0 积分 2021-08-18 加入
A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
13天前
已完结
Bayesian optimal interval design for dose finding in drug-combination trials
13天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
1个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
1个月前
已完结
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity
2个月前
已完结
Chimeric Antigen Receptor (CAR) T-Cell Therapy-Induced Cardiotoxicity: A Narrative Review of Mechanisms, Clinical Presentations, and Strategies for Optimization
3个月前
已完结
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
3个月前
已完结
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
4个月前
已完结
An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma
4个月前
已完结
CAR T cell–mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis
5个月前
已完结
皖公网安备34019202002308
